1. Scrip
  2. >>Therapy Areas

Pharma VC-Backed Incubator Cydan Launches Imara With $31.5m

 
• By Mandy Jackson

With more than a year lag between the launch of its first two startups, the venture capital- and big pharma VC-backed biotechnology incubator Cydan Development Inc. is on track to reach its goal of founding five orphan drug-focused firms in four years, including its second venture, Imara Inc.

With more than a year lag between the launch of its first two startups, the venture capital- and big pharma VC-backed biotechnology incubator Cydan Development Inc. is on track to reach its goal of founding five orphan drug-focused firms in four years, including its second venture, Imara Inc.

Cydan raised $26m in 2013 from two pharma-affiliated corporate VC funds, two venture capital firms and a biotech-focused real estate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.